Myocardial Metabolism of $^{123}$I-BMIPP in a Canine Model with Ischemia: Implications of Perfusion–Metabolism Mismatch on SPECT Images in Patients with Ischemic Heart Disease

Ryohei Hosokawa, Ryuji Nohara, Yasuhisa Fujibayashi, Kazumi Okuda, Motonari Ogino, Taku Hirai, Masatoshi Fujita, Nagara Tamaki, Junji Konishi and Shigetake Sasayama

Department of Cardiovascular Medicine and Nuclear Medicine, Graduate School of Medicine, and Faculty of Pharmaceutical Sciences, Kyoto University, Kyoto, Japan

$^{123}$I-(p-iodophenyl)-3-R,S-methylpentadecanoic acid (BMIPP) is a fatty acid analog for SPECT imaging. This radiopharmaceutical possesses the unique property, that is, perfusion–metabolism mismatch on SPECT images in patients with ischemic heart disease. However, the reason of this mechanism remains unclear. **Methods:** Using open-chest dogs under anesthesia, we made a system to release all the blood of the great cardiac vein outside without recirculation, if necessary. Left anterior descending artery (LAD) was occluded for 30 min after reperfusion. After the injection of BMIPP into LAD, blood samplings from the cardiac vein and abdominal aorta (6 dogs) or serial biopsy specimens from the LAD region (5 dogs) were performed, and then compared with the normal control. The metabolites of BMIPP, including backdiffusion of nonmetabolized BMIPP, were evaluated with high-performance liquid chromatography (HPLC) in the efflux study. Thin-layer chromatography (TLC) technique was introduced in the tissue analytical study. **Results:** Although the rapid extraction of BMIPP from the plasma into the myocardium and the subsequent retention were unchanged, the early washout (8 min) of radioactivity significantly increased (51% ± 12% to 65% ± 7%; $P < 0.05$) with ischemia. The metabolites from the myocardium consisted of backdiffusion of nonmetabolized BMIPP, α, intermediate, and full oxidation metabolites. Among these metabolites, backdiffusion of nonmetabolized BMIPP in blood significantly increased (27.9% ± 7.7% to 42.3% ± 8.1%; $P < 0.05$), especially in the early phase with ischemia. In tissue, the radioactivity was concentrated in the triglyceride pool even in the early phase, and in addition, BMIPP and α-oxidized metabolite significantly decreased in the early phase with ischemia ($t = 1$ min after BMIPP injection, 25.9% ± 8.6% to 14.5% ± 2.1%, $P < 0.01$; $t = 2$ min, 8.9% ± 5.0% to 4.5% ± 1.7%, $P < 0.05$). **Conclusion:** These results show that backdiffusion of nonmetabolized BMIPP from the myocardium increased and BMIPP (long-chain fatty acids) in tissue decreased with ischemia, suggesting backdiffusion of nonmetabolized BMIPP might play an important role in myocardial perfusion–metabolism mismatch on SPECT images in patients with ischemic heart disease.

**Key Words:** $^{123}$I-BMIPP; mismatch; ischemic heart disease; backdiffusion


Naturally occurring, long-chain fatty acids such as palmitic acid are the major energy source for the normoxic myocardium, and thus, radioiodinated fatty acid agents represent potential probes to evaluate differences in cardiac oxidative metabolism that are present in various myocardial disorders. However, straight-chain fatty acids are rapidly metabolized by β-oxidation, and thus, structural modifications have been proposed as a method of improving image quality. $^{123}$I-(p-iodophenyl)-3-R,S-methylpentadecanoic acid (BMIPP) is a radioiodinated fatty acid analog with a methyl branch at the β 3 position. This structure of BMIPP inhibits rapid myocardial catabolism (3,4), and thus, BMIPP has a long retention in the myocardium by incorporation into the triglyceride pool (3,4), showing good characteristics for clinical SPECT imaging. Many clinical protocols that use BMIPP have been performed in both Japan and western Europe, and several studies have reported that BMIPP possesses the unique property of perfusion–metabolism mismatch, that is, decreased BMIPP uptake with relatively preserved myocardial perfusion, on SPECT images in patients with ischemic heart disease (5–8).

Our previous study, which used an animal model, demonstrated that backdiffusion of BMIPP significantly increased in the early phase; the full metabolite of β-oxidation in the late phase also decreased from the dysfunctional myocardium created by etomoxir, a carnitine shuttle inhibitor; and in addition, total backdiffusion of BMIPP was significant (9). Our recent study also elucidated that backdiffusion of nonmetabolized BMIPP increased and full metabolite of complete β-oxidation decreased in proportion to the severity of ischemia with an occlusion and reperfusion canine model.
(10). However, the mechanism of perfusion–metabolism mismatch remains to be elucidated.

The purpose of this study was to examine the myocardial metabolism of BMIPP both in efflux of the blood and in tissue after regional ischemia and reperfusion, trying to explain the mechanism of perfusion–metabolism mismatch on SPECT images in patients with ischemic heart disease.

This study initially elucidated the mechanism of “mismatch” from the analyses both in efflux and in tissue with an animal model.

**MATERIALS AND METHODS**

This study followed the Guidelines for Animal Experiments of Kyoto University established in 1988.

After an overnight fast, adult male mongrel dogs weighing 21.0–29.5 kg were anesthetized by intramuscular injection of ketalar (2.5 mg/kg) for the induction, followed by intravenous injection of pentobarbital (25 mg/kg) for the maintenance of anesthesia. After endotracheal intubation, the animals were connected to a dual-phase control respirator (Harvard Apparatus, Southnatis, MA) supplying 100% oxygen at 2 L/min. A catheter was inserted into one femoral artery to monitor blood pressure, and another catheter for arterial blood sampling was inserted into the abdominal aorta through the opposite femoral artery. A triple-lumen intravenous catheter was placed in the femoral vein for fluid infusion and drug administration. Thoracotomy was performed at the fifth intercostal space, and the epicardium was fixed to the thoracic wall in the form of a cradle. The left anterior descending artery (LAD) was dissected free for radioisotope administration, and a Doppler flow probe and a snare were implanted around the proximal part of the LAD. As shown in Figure 1, the great cardiac vein (GCV) was also dissected free, cannulated, and a three-way value was attached to switch the blood flow to the left appendage of the heart for recirculation or to the open port for venous blood sampling. The colored microspheres were infused through the catheter into the left appendage for the measurement of regional myocardial blood flow (MBF). The catheter was later used for the injection of Evans Blue for the calculation of ischemic region. The wall tracker module that was used for ultrasonography (WT-10; Crystal Biotech, Hopkinton, MA) was attached to the LAD region of the left ventricle for the evaluation of regional wall thickening (Fig. 1).

**Experimental Protocol**

The experimental protocol is summarized in Figure 2. Surgical procedures were performed on 39 dogs. Twelve dogs died during surgery or procedures of the protocols despite resuscitation and were thus excluded from the study. Another 4 dogs were excluded from this study, 3 dogs because of acute myocardial infarction and 2 dogs because of inadequately decreased MBF during ischemia.

The remaining 23 dogs completed the protocol. Animals were divided into four groups: the control group of efflux study (the control efflux group, n = 6), the group of efflux study on ischemia (the ischemia efflux group, n = 6), the control group with tissue biopsy (the control biopsy group, n = 6), and the group with tissue biopsy on ischemia (the ischemia biopsy group, n = 5). In the efflux study on ischemia, 30-min LAD occlusion, followed by 20 min of reperfusion, was performed, and then the extraction, retention and metabolism studies were completed. In the biopsy study on ischemia, after 30-min LAD occlusion, followed by 20 min of reperfusion, the biopsy of serial tissue samplings were performed in the same way as the control.

**Measurement of Regional Myocardial Blood Flow**

MBF was measured four times with colored microspheres: at baseline, during LAD occlusion, after 20 min of reperfusion and the end of the protocol in the efflux study (Fig. 2). Red, yellow, blue and black colored microspheres were chosen in this study. In the biopsy study with ischemia, MBF was measured only at baseline and during LAD occlusion to validate the myocardial flow reduction. The colored microspheres were nonradioactive (E-Z Co. Ltd., Los Angeles, CA) and 7–10 million microspheres were injected into the left atrium with a syringe after sufficient manual mixing with another connected syringe. Concomitantly, blood samples were collected from the femoral artery at a rate of 10 mL/min by 90-s aspiration. After the dogs were killed, myocardial tissue samples (each piece weighing 0.5–1.0 g) were collected from 20 sites on the epicardial and endocardial layers of each ischemic and normal area. Each sample was then treated by routine methods, as previously reported (11). Microspheres were counted under a microscope at \( \times100–400 \) magnification, and regional MBF was quantified. Evans Blue and triphenyl tetrazolium chloride (TTC) stains did not affect this measurement.

**Measurement of Myocardial Thickening**

Myocardial thickening was assessed with a wall tracker module (WT-10; Crystal Biotech), as described in a previous report (12). The beginning and end of the systolic interval were determined from the onset of the initial uptake of left ventricular \( \Delta P/dt \) and 20 ms before peak negative \( \Delta P/dt \), respectively. Regional left ventricular wall function was estimated as net systolic thickening. The thickening fraction was calculated by dividing the transmural net systolic thickening by the end diastolic wall thickness.
Measurement of Metabolic Parameters

The blood sampling from the GCV and the abdominal aorta were performed to measure lactate and to estimate the ischemic condition. Lactate consumption was calculated as follows:

\[
\text{Lactate consumption} = \frac{\text{arterial lactate (mg/dl)} - \text{venous lactate (mg/dl)}}{\text{arterial lactate (mg/dl)}} \times 100 (\%)
\]

The oxygen saturation of blood in the GCV or the abdominal aorta was continuously monitored by OXIMETRIX 3 (Abbott Laboratories, Abbot Park, IL), and the change in the difference between venous blood and arterial blood values was considered to represent ischemia or flow reduction.

Evaluation of Ischemic Size

Just before the dogs were killed, Evans blue dye (1.0%, 100 mL) was injected through the left appendage, after the complete occlusion of the LAD with a snare. The stained left ventricle was then sectioned into 4–5 short axial slices of equal thickness (1–1.5 cm) from base to apex to evaluate the ischemic area. The stained and nonstained areas were traced, and the ischemic areas were calculated as a percentage of the whole cut surface on the both sides of each slice and were averaged and multiplied by the weight of the slice. All the ischemic sizes were summed up and expressed as a percentage of the left ventricular size.

Evaluation of Infarct Area

All slices were stained with 1%, 37°C TTC for 20 min to detect the infarct area. Dogs having shown apparent infarction were excluded from the study.

Extraction of BMIPP

This study followed our previous protocol (/3) and involved collection of all the blood from the GCV for 60 s just after the injection of a mixture of 123I-BMIPP (0.5 mCi) and 125I-bovine serum albumin (0.5 mCi) in 100 μL saline. The collected blood samples were weighed, and the radioactivity was measured by a well scintillation counter (ARC-350; ALOKA, Tokyo, Japan) with decay correction. The actual radioactive content of 123I and 125I in the samples was calculated with the crosstalk ratio obtained from the 123I standard sample (crosstalk from 125I to 123I was negligible). The average flow rate of the GCV was calculated from the weight of the blood samples and the extraction fraction as follows:

\[
\text{Extraction fraction} = 1 - \frac{[\text{123I in the blood (0–30 s)}]/[\text{123I injected}]}{[\text{125I in the blood (0–30 s)}]/[\text{125I injected}]}
\]

Retention and Metabolism of BMIPP in Efflux Study

Just after the extraction study, BMIPP (123I: 2 mCi, 0.2 mL) was injected into the LAD, and both venous blood from the GCV and arterial blood from the abdominal aorta were collected into heparinized tubes at various time intervals (30 s, 1 min, 2 min, 5 min, 10 min, 15 min and 30 min after injection). Plasma samples were separated by centrifugation at 3000 rpm for 10 min, and the radioactivity of a 0.1-mL aliquot was measured by a well scintillation counter as soon as possible. The remainder of the plasma was extracted twice with a 2:1 mixture of chloroform and methanol (14). The organic layer was then collected and evaporated, and the residue dissolved in 500 μL methanol for high-performance liquid chromatography (HPLC) analysis. An LC-6A chromatographic system (Shimadzu Co. Ltd., Kyoto, Japan) with a YMC-Pack ODS Column (20 × 150 + 20 × 50 mm, YMC Co. Ltd., Kyoto, Japan) were used for the HPLC analysis. The mobile phase was methanol:water:acetic acid (96:4:1) with a flow rate of 6 mL/min. After injection of the sample, the eluate was collected in 1-min fractions with a fraction collector. The radioactivity of each fraction was then measured with the well scintillation counter with decay correction.

Data Calculation in Efflux Study

The area under the curve (AUC) of time-activity data were calculated with trapezoid algorithm. The following parameters were also calculated:

1. Cumulative dose = injected dose × extraction fraction.
2. Washout dose (0.5–30 min) = AUC of (radioactivity in GCV
plasma — radioactivity in arterial plasma

\[ \times \text{average flow rate of GCV} \times \frac{100 - \text{hematocrit}}{100}. \]

3. Retention fraction at 30 min = 1 - washout dose/cumulative dose.

4. % washout in the early phase (8 min)

\[ \text{Washout dose (8 min)} = \frac{\text{Washout dose (30 min)}}{100}. \]

Also calculated was the percentage cumulative metabolite washout fraction (0.5–30 min).

From the total radioactivity in plasma and the fraction of each metabolite obtained by HPLC, the plasma metabolite levels were calculated. Washout of each metabolite from the myocardium was then estimated from the difference in the metabolite levels of arterial and GCV plasma. The extraction of BMIPP from the arterial plasma was taken into consideration as follows:

Washout of BMIPP = GCV content — arterial content

\[ \times (1 - \text{extration fraction}). \]

The AUC of metabolite washout was calculated with trapezoidal algorithm. The cumulative metabolite washout fraction (1–30 min) was then calculated as follows:

Cumulative metabolite washout fraction

\[ = \frac{\text{AUC of metabolite/sur}}{\text{of each metabolite AUC}}. \]

Metabolism of BMIPP in Biopsy Study

In the biopsy studies, \(^{125}\text{I}-\text{BMIPP}\) (2 mCi, 0.2 mL) was injected into the LAD, and the tissue needle biopsy of the LAD region was performed transmurally at 1, 2, 5, 10, 15 and 30 min after injection of radioisotope.

The tissue samples were then rinsed in a cold saline solution for 3–5 s to clear the tissue of blood, and these samples were frozen in ceramic bowls as soon as possible with liquid nitrogen. Each sample was then ground down with a pestle and was extracted with a 2:1 mixture of chloroform and methanol (14) immediately after the freezing procedure. An aliquot of the extract was chromatographed on thin-layer chromatography (TLC) plates (Silica gel-60; E Merck, Darmstadt, Germany) using a solvent system: n-hexane:diethyl ether:acetic acid (60:40:1), as previously reported (15). The radioactivity was measured by a well scintillation counter. The radiopeaks were identified by a comparison with the standard samples.

Statistical Analysis

All measured values were analyzed with Student t test, and serial changes with the analysis of variance (ANOVA) program. A value was expressed in terms of mean ± SD, and a value of \(P < 0.05\) was considered statistically significant.

RESULTS

Hemodynamics

There was no significant change in either heart rate or aortic blood pressure during all the experiments.

Regional Myocardial Blood Flow

MBF during the experiments with ischemia are summarized in Table 1. The MBF in the ischemic region was expressed as an absolute value and a percentage of the baseline control.

The percentage MBF in efflux study significantly decreased to 28.0% ± 17.5% during occlusion \((P < 0.001)\). However, percentage MBF after 20 min of reperfusion and at the end of the protocol did not change significantly.

The percentage MBF in biopsy study also significantly decreased to 17.6% ± 13.7% during occlusion \((P < 0.001)\), and this result validated myocardial flow reduction during occlusion in biopsy study. These two values were slightly different but did not achieve statistical significance.

Regional Myocardial Thickening

The changes in the thickening fraction were examined during the ischemia efflux study, and myocardial thickening in the LAD region was expressed as a percentage of the baseline control. The percentage myocardial thickening significantly decreased to −34.6% ± 13.1% \((P < 0.001)\) versus baseline) during ischemia. These values also significantly decreased after reperfusion (9.8% ± 8.4%; \(P < 0.001\) versus baseline) and at the end of the protocol (18.7% ± 13.4%; \(P < 0.001\) versus baseline).

Metabolic Parameters

Lactate consumption and oxygen saturation were measured in the efflux study with ischemia (Table 2). Lactate consumption during occlusion significantly decreased from 33.5% ± 10.1% to −16.5% ± 40.8% \((P < 0.01)\) compared with the baseline control; however, these values after reperfusion and at the end of the protocol did not change significantly. Arterial-venous difference of oxygen saturation significantly increased from 77.0% ± 3.8% to 82.2% ± 4.5% \((P < 0.05)\) during occlusion compared with the baseline, which represented ischemia or flow reduction because hemoglobin levels did not change during experimental protocols.

Ischemic Sizes

The ischemic areas in the LAD region were certified in all canine hearts and were used for the experiments with ischemia. The percentage of ischemic areas (the size of area at risk) was 22.5% ± 4.7% (the ischemia efflux group) and 21.9% ± 5.2% (the ischemia biopsy group). There was no significant difference between these two groups.

Infarct Area by Triphenyl Tetrazolium Chloride Staining

The apparent infarct areas by TTC staining in the LAD region were certified in 3 of 39 dogs used for the experiments. These 3 dogs were excluded from the study.

Metabolism of BMIPP in Efflux Study

Extraction, retention and percentage washout in the early phase are shown in Table 3. Although extraction (30 s) and retention (30 min) did not change significantly with ischemia, the percentage washout in the early phase (8 min) significantly increased from 51% ± 12% to 65% ± 7% \((P < 0.05)\) in ischemia.
A typical HPLC illustrated the identification of four major peaks, and the metabolites from the myocardium were divided into the following four groups: the full-oxidation metabolite of BMIPP (2-(p-iodyophenyl) acetic acid), the intermediate metabolites, the α-oxidation metabolite (14-(p-iodyophenyl)-2(α)-R,S-methyltridecanonic acid) and the backdiffusion of nonmetabolized BMIPP, as previously reported (9,10,13). The washout of each metabolite from the myocardium was calculated from these data, and the cumulative washout fraction of each metabolite (30 min) is shown in Table 4. In ischemia, the level of the full-oxidation metabolite formed by the complete β-oxidation decreased from 20.2% ± 9.2% to 11.7% ± 5.7% and the level of backdiffusion of nonmetabolized BMIPP increased from 27.9% ± 7.7% to 42.3% ± 8.1%. These changes achieved statistical significance (P < 0.05).

**Metabolism of BMIPP in Tissue**

From the TLC profiles of the standard samples, reference (Rf) values of triglyceride, BMIPP, α-oxidation metabolite, and full-oxidation metabolite were determined to 0.68, 0.35, 0.30, and 0.20, respectively. On the basis of these values, the fractions from Rf = 0.60–0.75 were defined as triglyceride, the fractions from Rf = 0.3–0.4 as BMIPP and α-oxidation metabolite (long-chain fatty acids) and the fractions from Rf = 0.2–0.3 as short-chain fatty acids (such as full-oxidation metabolite). And then, the fractions from Rf 0 to Rf 0.2 were regarded as polar lipids.

The metabolites in tissue were calculated from these data, and the percentage of each metabolite group is shown in Table 5. The majority of radioactivity was stored in a triglyceride pool, even in the early phase of both normal and ischemic tissue. However, the value of triglyceride fractions at 30 min after BMIPP administration significantly decreased from 84.4% ± 4.7% to 76.7% ± 7.8% (P < 0.05) with ischemia. This might be due to decreased adenosine triphosphate (ATP) with ischemia. BMIPP and α-oxidized metabolite significantly decreased in the early phase with ischemia (25.9% ± 8.6% to 14.5% ± 2.1%, P < 0.01, t = 1 min after BMIPP administration; 8.9% ± 5.0% to 4.5% ± 1.7%, P < 0.05, t = 2 min). This result was compatible with increased backdiffusion of BMIPP from the myocardium in the early phase with ischemia.

Figure 3 shows the comparison of metabolites in tissue and efflux between normal control and ischemia. This figure indicates that the reason why early washout (8 min) of radioactivity increased with ischemia was mainly due to increased backdiffusion of nonmetabolized BMIPP in efflux followed by decreased BMIPP (long-chain fatty acids) in tissue.

**DISCUSSION**

The results of this study demonstrate that the majority of BMIPP was stored in a triglyceride pool even in the early phase, either in normal or in ischemic tissue, and that, backdiffusion of nonmetabolized BMIPP increased from the myocardium, and BMIPP itself decreased in tissue with ischemia. These results suggest that backdiffusion of nonmetabolized BMIPP might play an important role in perfusion-metabolism mismatch on SPECT images in patients with ischemic heart disease.

The apparent unique, yet not well-understood property of BMIPP, is the mismatch often observed on SPECT images between regional distribution of BMIPP and flow tracers such as 301TlCI in patients with ischemic heart disease (5,6)
or hypertrophic cardiomyopathy (16). Animal studies with BMIPP have evaluated regional myocardial distribution of this tracer in various cardiac disease models such as hypertensive rats (17,18) or cardiomyopathic hamsters (19). The details, however, are still unclear. It has not yet been completely established if perfusion–metabolism mismatch on SPECT images with $^{123}$I-BMIPP is even related to the intracellular oxidative metabolism of BMIPP. There are a lot of studies indicating that increased backdiffusion of BMIPP is the cause of the mismatch on SPECT images; however, there are not many studies that have proved it yet. Matsunari et al. (20) demonstrated that the early clearance of radioactivity could be observed from the mismatch areas using dynamic SPECT, and they speculated that this phenomenon was due to backdiffusion of BMIPP. The real mechanism of “mismatch,” however, is still undetermined. The results of this study demonstrate that the increased washout of radioactivity in the early phase with ischemia was mainly due to the increased backdiffusion of nonmetabolized BMIPP in efflux followed by decreased BMIPP itself in tissue, suggesting that backdiffusion of nonmetabolized BMIPP might play an important part in perfusion–metabolism mismatch on SPECT images in patients with ischemic heart disease. In patients with hypertrophic cardiomyopathy, Tanaka et al. (21) reported that CD36, a myocardial long-chain fatty acid transporter, was involved in myocardial uptake of BMIPP. However, there have been some patients with hypertrophic cardiomyopathy whose SPECT images show low uptake and high clearance of BMIPP (22). These results suggest that the abnormal uptake of BMIPP was related not only to membrane disorder but to intracellular metabolic abnormality. Further examinations might be necessary to elucidate the metabolism of BMIPP in patients with hypertrophic cardiomyopathy.

### Clinical Implication

In human studies, many reports discussed the significance of “mismatch” on SPECT images with $^{123}$I-BMIPP. Franken et al. (5) reported that segments with more reduced BMIPP uptake than $^{99m}$Tc-sestamibi, that is, the mismatch segments, can correspond to either stunned or hibernating myocardium in patients with subacute myocardial infarction. They also showed that mismatching of BMIPP and sestamibi uptake can be predictive of long-term functional recovery after acute myocardial infarction more accurately than dobutamine echo cardiography (23). In addition, Hashimoto et al. (24) indicated that the assessment of the degree and improvement of perfusion–metabolism mismatch by $^{201}$TI and $^{123}$I-BMIPP SPECT at an acute stage of myocardial infarction might contribute to identifying a future recovery of postischemic myocardial dysfunction. Tamaki et al. (25) suggested that decreased BMIPP uptake relative to $^{201}$TI might be a valuable predictor of future cardiac events in patients with myocardial infarction. In animal studies, Fujibayashi et al. (26) demonstrated that the ATP content and the BMIPP accumulation showed a strong positive correlation in a murine model with the intervention of dinitrophenol. Also, Nohara et al. (27) indicated that the myocardial accumulation of BMIPP in the viable ischemic region showed a strong correlation with the ATP content using a canine model with ischemia. These studies indicated $^{123}$I-BMIPP could be useful for predicting myocardial viability, functional recovery and risk stratification. The results from this study indicate that BMIPP was well retained in the triglyceride pool of either normal or ischemic canine myocardium; however, the percentage washout in the early phase (8 min)

### TABLE 2

<table>
<thead>
<tr>
<th></th>
<th>Baseline</th>
<th>Occlusion</th>
<th>Perfusion</th>
<th>Final</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lactate consumption (%)</td>
<td>33.5 ± 10.1</td>
<td>-16.5 ± 40.8*</td>
<td>16.3 ± 26.2</td>
<td>34.6 ± 16.7</td>
</tr>
<tr>
<td>Oxygen saturation (%)</td>
<td>77.0 ± 3.8</td>
<td>82.2 ± 4.5†</td>
<td>75.3 ± 7.2</td>
<td>72.3 ± 8.6</td>
</tr>
</tbody>
</table>

*P < 0.01 compared with baseline.
†P < 0.05 compared with baseline.

### TABLE 3

<table>
<thead>
<tr>
<th></th>
<th>Normal control (%)</th>
<th>Ischemia (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Extraction (30 sec)</td>
<td>74 ± 12 (%)</td>
<td>77 ± 6 (%)</td>
</tr>
<tr>
<td>Retention (30 min)</td>
<td>89 ± 12 (%)</td>
<td>88 ± 6 (%)</td>
</tr>
<tr>
<td>Percentage washout (8 min)</td>
<td>50 ± 12 (%)</td>
<td>65 ± 7 (%)*</td>
</tr>
</tbody>
</table>

*P < 0.05 versus normal control.

### TABLE 4

<table>
<thead>
<tr>
<th></th>
<th>Normal control (%)</th>
<th>Ischemia (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Full-oxidation metabolite</td>
<td>20.2 ± 9.2</td>
<td>11.7 ± 5.7*</td>
</tr>
<tr>
<td>Intermediate metabolites</td>
<td>25.7 ± 9.9</td>
<td>27.3 ± 9.5</td>
</tr>
<tr>
<td>Alpha-oxidation metabolite</td>
<td>26.2 ± 4.3</td>
<td>18.7 ± 2.5†</td>
</tr>
<tr>
<td>Back diffusion of BMIPP</td>
<td>27.9 ± 7.7</td>
<td>42.3 ± 8.1†</td>
</tr>
</tbody>
</table>

*P < 0.05 compared with normal control.
†P < 0.01 compared with normal control.
increased with ischemia. Considering the difference in heart rate between dogs and humans, one can estimate that an 8-min period after BMIPP administration in a canine model corresponds to 15–20 min in humans (28), which corresponds to the usual period for the initiation of early SPECT imaging. Thus, one can safely say that increased washout from ischemic myocardium in the early phase may produce the mismatch on SPECT images. In addition, the increased washout from ischemic myocardium was mainly due to the increased backdiffusion of nonmetabolized BMIPP followed by decreased β-oxidation. Thus, backdiffusion of nonmetabolized BMIPP may contribute to mismatch on SPECT images in patients with ischemic heart disease.

Study Limitations

Although backdiffusion of nonmetabolized BMIPP contributed to perfusion–metabolism mismatch on SPECT images in patients with ischemic heart disease, a limitation that must be acknowledged is that the efflux protocol and the biopsy protocol were performed separately. Both protocols must be performed punctually, and bleeding and edema by tissue biopsy were inevitable. The precise procedure of both protocols at the same time might be impossible without contamination to each other.

Also, in the biopsy protocol of this study, wall thickening and metabolic parameters were not measured because of the muscle damage by biopsies being performed six times, inevitable bleeding by tissue samplings and necessity of hemostasis after biopsy, although hemodynamics did not change significantly during the protocol.

In the metabolic analysis using TLC, BMIPP and α-oxidation metabolite could not be separated from each other. This was the same result as previously reported (15). The separation of BMIPP from α-oxidation metabolite needs HPLC analysis, which requires 4 to 5 dogs killed at each timing after the administration of BMIPP, that is, at least 50 dogs are required in the biopsy protocols. This would be undesirable for the protection of animals. In addition, this study was enough to show that backdiffusion of BMIPP might play an important role of “mismatch” on SPECT images.

**TABLE 5**

Percentage Values of Radioactive Metabolites in Tissue

<table>
<thead>
<tr>
<th>Normal control</th>
<th>1 min</th>
<th>2 min</th>
<th>5 min</th>
<th>10 min</th>
<th>15 min</th>
<th>30 min</th>
</tr>
</thead>
<tbody>
<tr>
<td>Triglyceride (%)</td>
<td>42.3 ± 9.6</td>
<td>56.3 ± 6.8</td>
<td>70.0 ± 7.5</td>
<td>75.8 ± 8.4</td>
<td>81.9 ± 5.7</td>
<td>84.4 ± 4.7</td>
</tr>
<tr>
<td>Long-chain fatty acids (%)</td>
<td>25.9 ± 8.6</td>
<td>8.9 ± 5.0</td>
<td>4.0 ± 2.3</td>
<td>3.0 ± 1.4</td>
<td>2.0 ± 0.8</td>
<td>2.5 ± 1.0</td>
</tr>
<tr>
<td>Short-chain fatty acids (%)</td>
<td>3.9 ± 1.7</td>
<td>6.7 ± 4.0</td>
<td>9.1 ± 5.2</td>
<td>8.5 ± 5.6</td>
<td>4.1 ± 1.9</td>
<td>2.7 ± 1.9</td>
</tr>
<tr>
<td>Polar lipids (%)</td>
<td>28.2 ± 7.9</td>
<td>32.6 ± 8.2</td>
<td>22.0 ± 3.4</td>
<td>17.6 ± 8.6</td>
<td>12.3 ± 4.0</td>
<td>9.3 ± 4.9</td>
</tr>
<tr>
<td><strong>Ischemia</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Triglyceride (%)</td>
<td>49.2 ± 13.7</td>
<td>60.9 ± 15.2</td>
<td>63.2 ± 8.9</td>
<td>70.3 ± 12.0</td>
<td>74.7 ± 7.8</td>
<td>76.7 ± 7.6*</td>
</tr>
<tr>
<td>Long-chain fatty acids (%)</td>
<td>14.5 ± 2.1†</td>
<td>4.5 ± 1.7*</td>
<td>2.7 ± 0.7</td>
<td>3.0 ± 1.0</td>
<td>3.4 ± 2.3</td>
<td>3.0 ± 1.3</td>
</tr>
<tr>
<td>Short-chain fatty acids (%)</td>
<td>2.2 ± 1.0*</td>
<td>2.4 ± 1.0*</td>
<td>4.9 ± 1.9</td>
<td>6.4 ± 2.9</td>
<td>4.9 ± 1.8</td>
<td>3.4 ± 1.4</td>
</tr>
<tr>
<td>Polar lipids (%)</td>
<td>32.1 ± 14.4</td>
<td>30.5 ± 16.1</td>
<td>29.7 ± 9.2*</td>
<td>22.9 ± 12.5*</td>
<td>18.1 ± 7.8</td>
<td>13.5 ± 5.7</td>
</tr>
</tbody>
</table>

*P < 0.05 compared with normal control.  †P < 0.01 compared with normal control.

**FIGURE 3.** Mean washout of each metabolite from the myocardium (in efflux) and in myocardial tissue. Comparisons between normal control and ischemia. SHORT CHAIN = short-chain fatty acids catabolized from BMIPP, such as full-oxidation metabolite; AMIPT = α-oxidation metabolite; TG = triglyceride.
images because of the combined studies of biopsy with efflux.

CONCLUSION

Backdiffusion of nonmetabolized BMIPP increased and full-oxidation metabolite formed by complete β-oxidation decreased from the myocardium, and BMIPP (long-chain fatty acids) decreased in tissue with ischemia. Thus, increased backdiffusion of nonmetabolized BMIPP might play an important role in perfusion–metabolism mismatch on SPECT images in patients with ischemic heart disease.

ACKNOWLEDGMENTS

We thank Naoko Takimoto for secretarial assistance throughout the study and Keith A. Takechi for reading the manuscript. We also thank Nihon Medi-Physics Co. Ltd. (Tokyo, Japan) for product support and encouragement. Presented in part at the Third International Conference on Nuclear Cardiology, April 6–9, 1997, Florence, Italy.

REFERENCES